Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A new Gilead study shows that a single-tablet combo of HIV-fighting drugs could help patients who today take multiple drugs.

A NEW, single-dose malaria treatment combining four existing drugs has been found to be as effective as the standard three-day regimen, offering a potential breakthrough against one of Africa’s ...

The battle against HIV in sub-Saharan Africa has always been as much about systems and science as about the virus itself. Antiretroviral therapy has turned what was once a death sentence into a ...

The trial evaluated treatment responses in patients who were virologically suppressed, switching from a multi-tablet regimen ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Background “Prevention is better than cure,” they say. But what happens when prevention is no longer enough, when we have crossed that line and are confronted with the painful reality of a disease ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Richard Jefferys, a pioneering HIV advocate who helped open access to lifesaving drugs and clinical trials worldwide, will deliver the 29th Jonathan Lax Memorial Lecture at The Wistar Institute ...

In a new study, scientists discovered two FDA-approved cancer drugs that could also be effective at combatting one well-known ...

Renovaro Inc. lost its initial bid to roll back part of its deal for a bogus HIV cure peddled by a Turkish conman later convicted of killing a blackmailer to keep the fraudulent transaction on track.